Neutrophil-integrated syncytial CAR macrophage for cancer immunotherapy.

Neutrophil-integrated syncytial CAR macrophages significantly enhance tumor infiltration and therapeutic efficacy, reducing tumor burden and preventing recurrence in mouse models.

• Why it matters: Overcoming the limited effectiveness of CAR-M therapy is crucial for treating solid tumors, especially those with low antigen expression that evade immune responses.
• What they did: Researchers fused CAR macrophages with neutrophils to create S-CAR-Ms, which demonstrated improved tumor migration and increased tumor cell phagocytosis through multiple pathways in mouse models.
• The result: This approach enabled effective tumor reduction, metastasis limitation, and antigen spreading, offering a promising strategy to address the shortcomings of conventional CAR-M therapies for solid tumors.